Difference between the Two Types of Fixed-ratio Combination Basal Insulin and Glucagon-Like Peptide 1 Receptor Agonists Assessed Using Professional CGM

Abstract

For the treatment of diabetes mellitus, two combinations of long-acting insulin and GLP-1 receptor agonist with a fixed ratio combination (FRC) are available in Japan: insulin degludec and liraglutide (IDegLira), and insulin glargine and lixisenatide (IGlaLixi). We compared the differences in daily glucose levels to evaluate the characteristics of the glucose-lowering effect in Japanese patients with type two diabetes mellitus. The glucose-lowering effects of both types of FRC (IDegLira, and IGlaLixi), which were administered at the same dose, were evaluated in 24 patients with type 2 diabetes (female, n=16; male, n=8; age, 65.5±15.1 years; duration of diabetes, 16.3±10.6 years; HbA1c, 8.6±1.3 %; C-peptide index [CPI], 1.3±1.0). IGlaLixi showed a superior effect on TIR and TAR, as well as TBR. Thus, IGlaLixi was associated with greater safety. These results might be derived from differences in pharmacological characteristics between liraglutide and lixisenatide, insulin degludeg, and glargine, and the ratios of the combination of GLP-1 receptor agonists and insulin.